 Presentations will highlight new data on the safety, efficacy, and tolerability of once-daily, topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-daily, topical roflumilast foam for the treatment of scalp and body psoriasis and seborrheic dermatitis. Presentations will highlight new data on the safety, efficacy, and tolerability of once-daily, topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-daily, topical roflumilast foam for the treatment of scalp and body psoriasis and seborrheic dermatitis. 